Patents Assigned to Beigene, Ltd.
  • Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
    Patent number: 9670203
    Abstract: Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: June 6, 2017
    Assignee: BeiGene, Ltd.
    Inventors: Changyou Zhou, Guoliang Zhang
  • Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
    Patent number: 9617273
    Abstract: Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: April 11, 2017
    Assignee: BeiGene, Ltd.
    Inventors: Changyou Zhou, Bo Ren, Hexiang Wang
  • FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
    Publication number: 20170073349
    Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Applicant: BeiGene, Ltd.
    Inventors: Zhiwei WANG, Yunhang GUO
  • Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulators
    Patent number: 9556188
    Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: January 31, 2017
    Assignee: BeiGene, Ltd.
    Inventors: Zhiwei Wang, Yunhang Guo
  • Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators
    Patent number: 9447106
    Abstract: The invention is substituted 4,5-dihydro- and 4,5,6,7-tetrahydro-pyrazolo[1,5-?]pyrimidine compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor, such as inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: September 20, 2016
    Assignee: BeiGene, Ltd.
    Inventors: Zhiwei Wang, Yunhang Guo
  • Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
    Patent number: 9393232
    Abstract: Disclosed are substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compounds, pharmaceutical compositions comprising at least one such 4 substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compound processes for the preparation thereof, and the use thereof for inhibiting BET family of bromodomains and for treating disorders mediated thereby, such as certain cancers.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: July 19, 2016
    Assignee: BeiGene, Ltd.
    Inventors: Bo Ren, Changyou Zhou, Hexiang Wang
  • Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors
    Patent number: 9328111
    Abstract: The present invention provides a compound of Formula (I): wherein the variables Z, n, Y and p are as defined herein, and pharmaceutically acceptable salts thereof, which can inhibit the activity of poly (ADP-ribose)polymerases, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: December 31, 2011
    Date of Patent: May 3, 2016
    Assignee: BeiGene Ltd.
    Inventors: Changyou Zhou, Bo Ren, Hexiang Wang
  • Fused heterocyclic compounds as protein kinase inhibitors
    Publication number: 20160083392
    Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
    Type: Application
    Filed: November 25, 2015
    Publication date: March 24, 2016
    Applicant: Beigene, Ltd.
    Inventors: Zhiwei Wang, Yunhang Guo
  • Fused tricyclic compounds as Raf kinase inhibitors
    Patent number: 9273046
    Abstract: Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.
    Type: Grant
    Filed: December 31, 2011
    Date of Patent: March 1, 2016
    Assignee: BeiGene, LTD.
    Inventors: Changyou Zhou, Shaohui Wang, Guoliang Zhang
  • Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
    Patent number: 9260440
    Abstract: Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 31, 2011
    Date of Patent: February 16, 2016
    Assignee: BeiGene, Ltd.
    Inventors: Changyou Zhou, Bo Ren, Hexiang Wang
  • Anti-PD1 antibodies and their use as therapeutics and diagnostics
    Patent number: 9217034
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Grant
    Filed: March 2, 2014
    Date of Patent: December 22, 2015
    Assignee: BEIGENE, LTD.
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
  • Fused heterocyclic compounds as protein kinase inhibitors
    Publication number: 20150259354
    Abstract: The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.
    Type: Application
    Filed: May 27, 2015
    Publication date: September 17, 2015
    Applicant: Beigene, Ltd.
    Inventors: Zhiwei Wang, Yunhang Guo
  • Anti-PD1 Antibodies and their Use as Therapeutics and Diagnostics
    Publication number: 20150079109
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Application
    Filed: March 2, 2014
    Publication date: March 19, 2015
    Applicant: BeiGene, Ltd.
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
  • Anti-PD1 antibodies and their use as therapeutics and diagnostics
    Patent number: 8735553
    Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
    Type: Grant
    Filed: November 10, 2013
    Date of Patent: May 27, 2014
    Assignee: Beigene, Ltd.
    Inventors: Kang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng